William P. Sheridan
Net Worth

Last updated:

What is William P. Sheridan net worth?

The estimated net worth of Dr. William P. Sheridan is at least $18,448,371 as of 10 Mar 2022. He owns shares worth $311,602 as insider, has earned $5,545,249 from insider trading and has received compensation worth at least $12,591,520 in BioCryst Pharmaceuticals, Inc..

What is the salary of William P. Sheridan?

Dr. William P. Sheridan salary is $786,970 per year as Chief Medical Officer & Senior Vice President in BioCryst Pharmaceuticals, Inc..

How old is William P. Sheridan?

Dr. William P. Sheridan is 70 years old, born in 1955.

What stocks does William P. Sheridan currently own?

As insider, Dr. William P. Sheridan owns shares in one company:

Company Title Shares Price per share Total value
BioCryst Pharmaceuticals, Inc. (BCRX) Chief Medical Officer & Senior Vice President 37,954 $8.21 $311,602

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX logo
BCRX
BioCryst Pharmaceuticals, Inc.
$8.21

William P. Sheridan insider trading

BioCryst Pharmaceuticals, Inc.

Dr. William P. Sheridan has made 19 insider trades between 2009-2022, according to the Form 4 filled with the SEC. Most recently he sold 1,400 units of BCRX stock worth $24,696 on 10 Mar 2022.

The largest trade he's ever made was exercising 159,739 units of BCRX stock on 10 Mar 2022. As of 10 Mar 2022 he still owns at least 37,954 units of BCRX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 1,400 $17.64 $24,696
Option
Emp. Stock Option (Right to Buy) 148,302 $3.22 $477,532
Sale
Common Stock 159,739 $16.87 $2,694,797
Option
Common Stock 148,302 $3.22 $477,532
Option
Emp. Stock Option (Right to Buy) 21,614 N/A N/A
Option
Common Stock 91,814 $5.26 $482,666
Sale
Common Stock 91,814 N/A N/A
Option
Common Stock 91,814 N/A N/A
Option
Common Stock 71,759 $5.26 $377,237
Sale
Common Stock 71,759 N/A N/A
Option
Emp. Stock Option (Right to Buy) 71,759 N/A N/A
Option
Emp. Stock Option (Right to Buy) 71,759 $5.26 $377,237
Option
Common Stock 71,759 N/A N/A
Option
Stock Option (Right to Buy) 41,250 N/A N/A
Option
Common Stock 41,250 N/A N/A
Sale
Common Stock 41,250 N/A N/A
Sale
Common Stock 20,488 $7.58 $155,299
Option
Emp. Stock Option (Right to Buy) 62,500 $1.42 $88,750
Option
Common Stock 62,500 $1.42 $88,750
Sale
Common Stock 62,500 $1.42 $88,750
Sale
Common Stock 42,112 $2.58 $108,649
Option
Emp. Stock Option (Right to Buy) 42,112 $2.58 $108,649
Option
Common Stock 42,112 $2.58 $108,649
Sale
Common Stock 64,310 $4.72 $303,543
Option
Common Stock 70,389 $2.58 $181,604
Sale
Common Stock 70,389 $2.58 $181,604
Option
Emp. Stock Option (Right to Buy) 70,389 $2.58 $181,604
Sale
Common Stock 23,104 $12.06 $278,634
Option
Common Stock 23,104 $12.06 $278,634
Option
Emp. Stock Option (Right to Buy) 23,104 $12.06 $278,634
Option
Common Stock 48,396 $4.11 $198,762
Option
Emp. Stock Option (Right to Buy) 31,396 $3.44 $107,845
Sale
Common Stock 105,295 $12.43 $1,308,817
Option
Emp. Stock Option (Right to Buy) 7,478 $5.71 $42,662
Option
Stock Option (Right to Buy) 13,750 $4.15 $57,063
Option
Common Stock 21,228 $5.19 $110,110
Option
Emp. Stock Option (Right to Buy) 16,407 $1.2 $19,688
Option
Common Stock 16,407 $1.2 $19,688
Sale
Common Stock 956 $4.78 $4,570
Option
Emp. Stock Option (Right to Buy) 18,593 $1.89 $35,141
Option
Common Stock 18,593 $1.89 $35,141
Sale
Common Stock 18,593 $8.01 $148,856
Option
Emp. Stock Option (Right to Buy) 4,166 $2.58 $10,748
Sale
Common Stock 4,166 $2.58 $10,748
Option
Common Stock 4,166 $2.58 $10,748
Sale
Common Stock 4,167 $2.58 $10,751
Option
Common Stock 4,167 $2.58 $10,751
Option
Emp. Stock Option (Right to Buy) 4,167 $2.58 $10,751
Sale
Emp. Stock Option (Right to Buy) 4,167 $2.58 $10,751
Sale
Emp. Stock Option (Right to Buy) 62,499 $2.58 $161,247
Sale
Common Stock 6,000 $8.92 $53,538
Purchase
Common Stock 3,000 $1.62 $4,845

BioCryst Pharmaceuticals key executives

BioCryst Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: